Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 28.51% is in line with its 5-year average of 29.33%, near the low end of its 5-year range (26.82%–33.23%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.67% below its 12-month average of 28.99%.
Reported quarterly gross margin; no daily interpolation.
GROSS MARGIN
28.51%
GROSS MARGIN AVG TTM
28.99%
GROSS MARGIN AVG 3Y
29.44%
GROSS MARGIN AVG 5Y
29.14%
GROSS MARGIN AVG 10Y
29.48%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.67%
CURRENT VS 3Y AVG
-3.18%
CURRENT VS 5Y AVG
-2.16%
CURRENT VS 10Y AVG
-3.30%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
58.69%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-51.43%
vs the sector median at left
Medpace Holdings, Inc.
Market Cap
$16.41B
Gross Margin
28.51%
TTM Avg
28.99%
3Y Avg
29.44%
5Y Avg
29.14%
Market Cap
$15.15B
Gross Margin
54.69%
TTM Avg
54.56%
3Y Avg
56.03%
5Y Avg
57.27%
Market Cap
$14.60B
Gross Margin
64.37%
TTM Avg
63.66%
3Y Avg
64.40%
5Y Avg
64.61%
Market Cap
$14.13B
Gross Margin
30.08%
TTM Avg
33.76%
3Y Avg
35.72%
5Y Avg
36.84%
Market Cap
$18.99B
Gross Margin
61.62%
TTM Avg
66.54%
3Y Avg
68.95%
5Y Avg
69.55%
Market Cap
$12.56B
Gross Margin
32.24%
TTM Avg
31.70%
3Y Avg
34.15%
5Y Avg
35.17%
Market Cap
$12.52B
Gross Margin
66.48%
TTM Avg
69.16%
3Y Avg
69.73%
5Y Avg
70.75%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $16.41B | 28.51% | 28.99% | 29.44% | 29.14% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 61.00% | 58.14% | 57.33% | 59.28% |
| Solventum Corporation (SOLV)vs › | $15.15B | 54.69% | 54.56% | 56.03% | 57.27% |
| The Cooper Companies, Inc. (COO)vs › | $14.60B | 64.37% | 63.66% | 64.40% | 64.61% |
| Baxter International Inc. (BAX)vs › | $14.13B | 30.08% | 33.76% | 35.72% | 36.84% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.99B | 61.62% | 66.54% | 68.95% | 69.55% |
| Revvity, Inc. (RVTY)vs › | $12.83B | 52.11% | 50.55% | 50.58% | 52.43% |
| Charles River Laboratories International, Inc. (CRL)vs › | $12.56B | 32.24% | 31.70% | 34.15% | 35.17% |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 66.48% | 69.16% | 69.73% | 70.75% |
| Viatris Inc. (VTRS)vs › | $20.55B | 34.40% | 36.61% | 38.73% | 36.31% |
Gross Margin
28.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 28.51% |
| 2026-03-31 | 27.78% |
| 2025-12-31 | 28.98% |
| 2025-09-30 | 29.84% |
| 2025-06-30 | 29.84% |
| 2025-03-31 | 31.93% |
| 2024-12-31 | 33.23% |
| 2024-09-30 | 31.69% |
| 2024-06-30 | 29.13% |
| 2024-03-31 | 30.36% |
| 2023-12-31 | 27.45% |
| 2023-09-30 | 27.04% |
| 2023-06-30 | 26.97% |
| 2023-03-31 | 29.99% |
| 2022-12-31 | 29.37% |
| 2022-09-30 | 31.02% |
| 2022-06-30 | 28.19% |
| 2022-03-31 | 29.82% |
| 2021-12-31 | 28.52% |
| 2021-09-30 | 29.47% |
| 2021-06-30 | 26.82% |
| 2021-03-31 | 30.17% |
| 2020-12-31 | 31.91% |
| 2020-09-30 | 32.19% |
| 2020-06-30 | 27.63% |
| 2020-03-31 | 28.19% |
| 2019-12-31 | 27.27% |
| 2019-09-30 | 29.67% |
| 2019-06-30 | 29.79% |
| 2019-03-31 | 27.42% |
| 2018-12-31 | 31.74% |
| 2018-09-30 | 30.83% |
| 2018-06-30 | 31.43% |
| 2018-03-31 | 28.10% |
| 2017-12-31 | 38.94% |
| 2017-09-30 | 41.16% |
| 2017-06-30 | 40.10% |
| 2017-03-31 | 40.03% |
| 2016-12-31 | 40.93% |
| 2016-09-30 | 40.44% |
| 2016-06-30 | 40.96% |
| 2016-03-31 | 40.99% |
| 2015-12-31 | 43.17% |
| 2015-09-30 | 43.28% |
| 2015-06-30 | 43.43% |
| 2015-03-31 | 44.45% |
| 2014-03-31 | 40.41% |
